Get started
Author

Grzegorz Czyżewicz

Observed names: Czyżewicz, Grzegorz, Czyżewicz, Grzegorz; Oddział Onkologiczny, Krakowski Szpital Specjalistyczny im. Jana Pawła II, G Czyzewicz, G Czyżewicz, G. Czyzewicz, G. Czyżewicz, Grzegorz Czyzewicz
OpenAlex ID: A5077510505
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
2014 · Edward B Garon, Tudor-Eliade Ciuleanu, et al. · The Lancet · 1,319
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
2021 · Hossein Borghaei, Scott Gettinger, et al. · Journal of Clinical Oncology · 684
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
2025 · Luis Paz-Ares, Hossein Borghaei, et al. · The Lancet · 114
OA14.04 Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC
2019 · S. Gettinger, H. Borghaei, et al. · Journal of Thoracic Oncology · 37
Decreased Levels of Histidine-Rich Glycoprotein in Advanced Lung Cancer: Association with Prothrombotic Alterations
2019 · Aleksandra Winiarska, Lech Zareba, et al. · Disease Markers · 31
PDF
The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients
2019 · Adam Szpechcinski, Mateusz Florczuk, et al. · Cellular and Molecular Life Sciences · 27
PDF
KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).
2020 · Charles M. Rudin, Mark M. Awad, et al. · Journal of Clinical Oncology · 26
OA12.06 First-Line Pembrolizumab or Placebo Combined with Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-Term Follow-Up Results
2022 · C.M. Rudin, H.R. Kim, et al. · Journal of Thoracic Oncology · 18
REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy.
2014 · Maurice Perol, Tudor-Eliade Ciuleanu, et al. · Journal of Clinical Oncology · 17
The comparison between Caprini and Padua VTE risk assessment models for hospitalised cancer patients undergoing chemotherapy at the tertiary oncology department in Poland: is pharmacological thromboprophylaxis overused?
2018 · Robert F. Łukaszuk, Justyna Dolna-Michno, et al. · Współczesna Onkologia · 16
PDF
Altered fibrin clot properties in advanced lung cancer: impact of chemotherapy
2018 · Grzegorz Królczyk, Michał Ząbczyk, et al. · Journal of Thoracic Disease · 15
PDF
Detection of EGFR mutations in liquid biopsy samples using allele-specific quantitative PCR: A comparative real-world evaluation of two popular diagnostic systems
2021 · Adam Szpechcinski, Maciej Bryl, et al. · Advances in Medical Sciences · 13
PDF
Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial.
2025 · Luis G. Paz-Ares, Hossein Borghaei, et al. · Journal of Clinical Oncology · 11
PDF
Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial
2017 · Suresh S. Ramalingam, Maurice Pérol, et al. · Clinical Lung Cancer · 11
Altered fibrin clot properties in advanced lung cancer: strong impact of cigarette smoking
2019 · Michał Ząbczyk, Grzegorz Królczyk, et al. · Medical Oncology · 9
PDF
Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC
2020 · M. Lind, S. Gettinger, et al. · Lung Cancer · 7
Pembrolizumab-combination therapy for NSCLC- effectiveness and predictive factors in real-world practice
2024 · Magdalena Knetki-Wróblewska, Rafał Dziadziuszko, et al. · Frontiers in Oncology · 5
PDF
Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03)
2021 · Francesco Grossi, Piotr Jaśkiewicz, et al. · Therapeutic Advances in Medical Oncology · 5
Treatment Patterns, Testing Practices, and Outcomes in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer in Poland: A Descriptive Analysis of National, Multicenter, Real-World Data from the REFLECT Study
2023 · Adam Pluzanski, Maciej Bryl, et al. · Cancers · 3
PDF
Effectiveness of Osimertinib in Patients with Lung Adenocarcinoma in Clinical Practice—The Expanded Drug Access Program in Poland
2020 · Magdalena Knetki-Wróblewska, Dariusz Kowalski, et al. · Advances in respiratory medicine · 3
PDF
Epidermal growth factor receptor Mutation status: Does younger mean more frequently mutated?
2017 · P Wójcik, P Krawczyk, et al. · Balkan Journal of Medical Genetics · 2
PDF
Ocena wpływu chemioterapii na czas przeżycia i wybrane objawy wpływające na jakość życia chorych na niedrobnokomórkowego raka płuca w IIIB i IV stopniu zaawansowania
2007 · Janusz Rolski, Tomasz Zemełka, et al. · Advances in respiratory medicine · 2
PDF
P2.13-14 The Clinical Usefulness of Liquid Biopsy for Detection and Dynamic Monitoring of EGFR T790M in NSCLC Patients on EGFR-TKI Therapy
2018 · A. Szpechcinski, K. Duk, et al. · Journal of Thoracic Oncology · 1
PDF
P3.01-041 The Robustness of Allele-Specific qPCR Assays for Detection of EGFR Mutations in Plasma Cell-Free DNA from NSCLC Patients
2017 · A. Szpechcinski, K. Duk, et al. · Journal of Thoracic Oncology · 1
PDF
EP12.11: Real-World Outcomes of Polish Patients With ALK-Positive NSCLC Treated With Brigatinib: 1-Year Results (ENTIRETY Study)
2026 · K. Stencel, G. Czyżewicz, et al. · Journal of Thoracic Oncology
Works count: 53
Citation count: 2,377
H-index: 12
I10-index: 14
Year
Topic
Type